# A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

> **NCT06883305** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 990 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **BIOLOGICAL:** Tezepelumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06883305
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-18
- **Primary completion:** 2029-03-13
- **Final completion:** 2029-06-05
- **Target enrollment:** 990 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06883305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06883305, "A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT06883305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*